From May 3rd to May 11th, 2026, medical device and pharmaceutical affairs news saw a series of developments, including a review of adverse event reporting operations following revisions to the Pharmaceutical and Medical Device Act (PMD Act), global partnerships in the endoscopic treatment robot sector, business expansion of surgical support AI, approval of regenerative medicine products, and financial results announcements from medical-related companies.
This article goes beyond a mere news summary, organizing the week's notable movements from the perspectives of medical device development, regulatory submissions, market launch strategies, and business development.
This Week's Highlights
- Revision of Malfunction Reporting Operations Following the Revised PMD Act
The practical application of the 30-day reporting requirement for known deaths or serious adverse events concerning foreign medical devices and foreign regenerative medical products has been revised.
- Olympus Signs Global Distribution Agreement with South Korean Company EndoRobotics
This collaboration could accelerate the adoption of robot-assisted technology in advanced endoscopic treatments, including ESD.
- Increased Activity Among Startups in Surgical Support AI, Non-Invasive Sensors, and Medical RI
Medical device and medical technology startups such as Anaut, Light Touch Technology, and NovAccel are making significant progress in commercializing their businesses.
- Regenerative Medical Product for Meniscus Injury Approved
Fujifilm Toyama Chemical's "Saviscus® Injection" has been approved as the first regenerative medical product for meniscus injury in Japan.
- Medical-Related Companies' Financial Results Season Kicks Off
Medical device, medical IT, and pharmaceutical companies reported mixed results, with highlights including growth investments, impairments, overseas sales, and royalty income.
1. Regulatory Affairs Updates
Review of 30-Day Reporting for Known Deaths and Serious Incidents involving Foreign Medical Devices
Effective May 1, 2026, with the partial enforcement of the revised laws and ministerial ordinances, the operational procedures for reporting known deaths or serious incidents involving foreign medical devices within 30 days have been revised.
A Ministry of Health, Labour and Welfare (MHLW) notification indicates that 30-day reporting for known deaths or serious incidents involving foreign medical devices will no longer be required. Furthermore, for products designated for post-market surveillance (PMS) evaluation, information on incidents occurring overseas will be requested as relevant information for PMS evaluation.
Similarly, a review of 30-day reporting for known deaths or serious incidents has also been conducted for foreign regenerative medical products.
Practical Points
This revision does not mean that all foreign incident information will become unnecessary. The key point is that while the handling of 30-day reports for known deaths and serious incidents is being reviewed, there will be cases where the organization of foreign incident information is required as relevant information for post-market surveillance evaluation.
Medical device marketing authorization holders (MAHs) and special approval holders for foreign-manufactured medical devices must confirm the following:
- Whether their own products fall under the scope of PMS evaluation.
- Whether their system for collecting, evaluating, and recording foreign incident information is appropriate.
- The distinction between information that is exempt from 30-day reporting and information that still requires evaluation and management.
- The necessity of reviewing GVP procedures, internal SOPs, and information sharing procedures with overseas manufacturers.
- Updating internal training regarding practical reporting to the PMDA.
MK Consulting's Perspective
This revision should not be viewed as a simple "reduction of reporting burden," but rather as a move to reorganize when, in what format, and under what regulatory context overseas safety information should be evaluated.
Especially in supporting the entry of overseas manufacturers into the Japanese market, it is crucial how incident information held by foreign manufacturers connects with Japan's GVP and PMS requirements. Even if information is treated as "known in the home country" by the overseas headquarters, in Japan, it may still require judgment regarding evaluation, recording, and reporting. Therefore, it is important to clearly define the roles and responsibilities with domestic MAHs.
2. Noteworthy News in the Medical Device and Endoscopy Sector
Olympus Signs Global Distribution Agreement with South Korean Company EndoRobotics
Olympus has signed an exclusive global distribution agreement with South Korean company EndoRobotics for robot-assisted technology for endoscopic treatment.
According to the company's announcement, Olympus plans to globally distribute the robot-assisted technology manufactured by EndoRobotics as part of its endoscopic treatment portfolio. Target areas are expected to include advanced endoscopic treatments such as Endoscopic Submucosal Dissection (ESD).
Why This Is Important
In the field of gastrointestinal endoscopy, endoscopes, accessories, energy devices, hemostatic devices, and stents have traditionally developed independently. However, for advanced procedures like ESD, challenges often arise regarding differences in surgeon skill, procedure time, risk of complications, and standardization of education and training. Robot-assisted technology has the potential to address these challenges.
This partnership indicates a shift in endoscopic treatment from "standalone devices" to a platform-based medical device combining endoscopes, accessories, robot assistance, AI, and imaging information.
MK Consulting's Perspective
Endoscopic treatment robots are not merely new devices; they also involve the following regulatory considerations:
- Combination assessment with existing endoscopic accessories
- Risk analysis of operational assistance functions
- Electrical safety, mechanical safety, and software validation
- Usability evaluation
- Clarification of clinical positioning
- Explanation of differences from existing procedures
- Consistency between overseas and domestic approvals
Moving forward, it may become crucial for endoscopic accessory manufacturers and component manufacturers to develop products with compatibility and combination use with robot-assisted technology in mind.
3. Medical AI and Startup Trends
Anaut Launches "EUREKA Inside," an AI Platform for Operating Rooms
Anaut announced the official launch of "EUREKA Inside" on May 1, 2026, as a new business venture for its surgical support AI, "EUREKA."
"EUREKA" has been developed as a surgical support AI that assists in recognizing anatomical structures in intraoperative images. "EUREKA Inside" goes beyond a standalone AI medical device; it is a concept to integrate AI into next-generation endoscopes, surgical robots, 3D viewers, OR integration software, and more.
Practical Points
For medical AI, regulatory considerations change depending on whether it aims for approval/certification as a standalone program or is evaluated as an integrated component within other medical devices.
For embedded AI, the following points are particularly important:
- Positioning of the AI software
- Applicability as a medical device program
- Responsibility demarcation with the parent device
- Change management for trained models
- Design of performance evaluation data
- Cybersecurity measures
- Post-market performance maintenance and update management
MK Consulting's Perspective
For future surgical support AI, it will be crucial not only to consider "what the AI can do on its own" but also which medical device it will be integrated into, what function it will serve, and under what risk classification.
When AI vendors and medical device manufacturers collaborate on development, it is essential to clarify the division of roles for regulatory responsibility, design control, change control, and post-market safety management at the contract stage.
Light Touch Technology Raises Additional 500 Million Yen for Non-Invasive Glucose Sensor
Light Touch Technology has raised 500 million yen in a Series B extension round, aiming to develop and globally expand its non-invasive blood glucose sensor. The cumulative amount raised is approximately 1.2 billion yen.
The company is developing technology that aims to measure blood glucose without the need for blood sampling, which could potentially reduce the burden on diabetic patients and lower infection risks.
Practical Points
While non-invasive blood glucose sensors hold great promise for reducing patient burden, they face high hurdles in terms of regulatory affairs and clinical evaluation. Especially since blood glucose measurement directly impacts treatment decisions, the following points are crucial:
- Correlation and agreement with existing blood glucose measurement methods
- Clinically acceptable range of measurement accuracy
- Performance in hypoglycemia and hyperglycemia ranges
- Influence of skin condition, individual differences, and measurement environment
- Necessity of calibration
- Variability in operation by users
- Differences in regulatory requirements for international expansion
MK Consulting's Perspective
For non-invasive measurement devices, the stronger the product concept's appeal, the more strictly regulatory bodies will scrutinize "what clinical decisions the performance can support." The required evaluation data varies significantly depending on whether the device aims for diagnostic aid, treatment decision-making, monitoring, or screening, beyond merely displaying measurement values.
NovAccel Raises 1.2 Billion Yen for Medical RI Production
NovAccel has raised a total of 1.2 billion yen in a post-seed round. The company aims to establish a stable supply system for Actinium-225 (Ac-225), which is gaining attention for Targeted Alpha Therapy (TAT). To achieve this, NovAccel is working on establishing an international procurement network for Radium-226 (Ra-226), the raw material for Ac-225, and developing and manufacturing the compact superconducting accelerator "RiSA."
Practical Points
Medical radioisotopes (RIs) are an area where pharmaceuticals, medical devices, radiation management, manufacturing facilities, and supply chains intersect. For next-generation cancer treatments like TAT to become widespread, it's crucial to have not only the treatment technology but also a stable supply of radionuclides, quality control, logistics, and acceptance systems on the part of medical institutions.
MK Consulting's Perspective
In the commercialization of medical technology, there are areas where supply constraints become a bottleneck, in addition to clinical value. Medical RIs are a prime example, requiring business design that encompasses regulatory compliance, manufacturing facilities, quality assurance, transportation, and radiation safety management.
4. Trends in Regenerative Medical Products and Clinical Trials
Fujifilm Toyama Chemical Obtains Approval for Regenerative Medical Product "SAIBISCAS® Injection" for Meniscus Injury
Fujifilm Toyama Chemical has obtained manufacturing and marketing approval in Japan for "SAIBISCAS® Injection," a regenerative medical product for meniscus injury. This product is a regenerative medical product that uses autologous synovial mesenchymal stem cells isolated and cultured from the patient's own synovial tissue.
According to the company's announcement, it is the first regenerative medical product for meniscus injury in Japan. Amid concerns about the long-term risk of osteoarthritis after meniscectomy, this product is expected to be a new treatment option that enables meniscus preservation.
Practical Points
Compared to medical devices and pharmaceuticals, regenerative medical products present stronger considerations regarding manufacturing management, quality control, equivalence evaluation, facility operations, and patient-specific individualization. Especially for products using autologous cells, the following points are crucial:
- Process management from collection to administration
- Quality control of cell processing
- Concept of manufacturing lots
- Operational collaboration with medical institutions
- Storage and transportation conditions
- Post-market safety measures
- Design of insurance coverage and reimbursement prices
MK Consulting's Perspective
Even after obtaining approval, the key to the widespread adoption of regenerative medical products lies in "which medical institutions, with what operational system, and to which patients they will be provided." Approval is not the goal; a launch strategy encompassing manufacturing, supply, facility operations, and insurance coverage is essential.
CoreTissue BioEngineering Initiates Randomized Comparative Cohort for ACL Reconstruction Medical Device
CoreTissue BioEngineering announced the completion of a safety evaluation cohort and the initiation of a randomized comparative cohort to verify the efficacy and safety of its medical device "Tissue Regenerative Ligament" (development code: CT-ACL001) for anterior cruciate ligament (ACL) reconstruction treatment.
Practical Points
For reconstructive and regenerative medical devices in the orthopedic field, a multifaceted evaluation is required, encompassing not only short-term safety but also tissue regeneration, mechanical strength, re-rupture rates, return to sports, and long-term outcomes.
Initiating a randomized comparative cohort is a crucial step in clinically demonstrating product value.
MK Consulting's Perspective
For regenerative and reparative medical devices, comparative study design against existing treatments is critical. If it's not clear "what makes it superior to standard treatment," the persuasive power will be weak, not only during the approval review process but also when seeking insurance coverage and explaining its introduction to medical institutions.
5. Financial Trends of Medical Device, Medical IT, and Healthcare-Related Companies
In early May 2026, the announcement of financial results for companies with fiscal years ending in March gained full momentum. While medical device, medical IT, and pharmaceutical companies saw growth in overseas sales and royalty income, some also experienced profit downturns due to impairment losses and revisions to supply plans.
Medical Devices and Medical IT
| Company | Category | Key Details | Perspective |
|---|---|---|---|
| Sysmex | Medical Devices / Diagnostics | Revised earnings forecast for the fiscal year ending March 2026. Due to the recording of impairment losses, profit attributable to owners of parent is forecast at JPY 35 billion. | A situation where not only the strength of existing businesses but also changes in the business environment after M&A and goodwill valuation affect performance. |
| M3 | Medical IT / Medical Platform | For the fiscal year ending March 2026, revenue is JPY 351.3 billion, and profit attributable to owners of parent is JPY 49.1 billion. | Growth continues in medical-related services such as medical IT, clinical trials, and marketing support. Should be viewed in a different category from medical device manufacturers. |
| Hoshi Medical Oxygen | Medical Services | A company focused on home healthcare and medical gas-related services. While revenue is trending upward, attention should be paid to the impact of rising costs. | Stability exists due to the aging population and demand for home healthcare, but it is susceptible to the impact of logistics, personnel, and equipment costs. |
Pharmaceuticals and Regenerative Medicine Related
| Company | Key Content | Perspective |
|---|---|---|
| Daiichi Sankyo | Revised full-year earnings forecast for the fiscal year ending March 2026 due to a review of ADC-related supply plans. | While ADCs are a growth area, supply systems, manufacturing capacity, and the division of responsibilities with partners significantly impact performance. |
| Ono Pharmaceutical | Revenue of 515.7 billion JPY for the fiscal year ending March 2026. Record-high revenue, and increased core net profit. | A structure where the maturation of domestic flagship products is offset by overseas product sales and royalty income. For the next fiscal year and beyond, attention should be paid to the impact of partnership terminations and R&D investments. |
| Kyowa Kirin | Revenue of 118.5 billion JPY and quarterly profit of 12.0 billion JPY for the first quarter of the fiscal year ending December 2026. | Global strategic products and technology income contribute to performance. Also, pay attention to R&D and site reorganization efforts. |
| Zeria Pharmaceutical | Sales of 89.1 billion JPY and operating profit of 12.3 billion JPY for the fiscal year ending March 2026. Ordinary profit and net profit decreased due to exchange rate losses, etc. | Stable growth of flagship products exists, but susceptible to exchange rates and overseas business impacts. |
MK Consulting's Perspective
When reviewing the financial results of healthcare-related companies, it's crucial to consider not just simple increases in revenue and profit, but also the following points:
- Reimbursement price and drug price revision risks for flagship products
- Ratio of overseas sales
- Sustainability of royalty income
- Impairment risk for goodwill and intangible assets after M&A
- Supply plans, manufacturing capacity, and reliance on contractors
- Progress of new product pipelines
- Speed of market launch after approval acquisition
- Prospects for insurance coverage and reimbursement prices
Especially in the medical device sector, business commercialization is not complete simply by obtaining approval or certification. It is necessary to evaluate business viability, including sales channels, physician evaluation, insurance reimbursement, manufacturing costs, and supply stability.
6. This Week's Insights on Regulatory Affairs and Business Development
The major trends visible from this week's news are the following three points:
1. Medical Devices Are Shifting from "Stand-alone Products" to "Platforms"
The partnership between Olympus and EndoRobotics, and Anaut's EUREKA Inside, demonstrate that medical devices are moving away from being stand-alone products and towards platforms that combine endoscopes, robots, AI, software, and imaging information.
In this trend, regulatory strategies focusing solely on the approval or certification of individual items are no longer sufficient. Designs must now encompass combination use, software updates, change management, cybersecurity, usability, and the utilization of post-market data.
2. Regulatory Compliance Shifts from "Whether to Report" to "How to Evaluate and Manage"
Revising the operation of defect reporting isn't just about the number of reports or reporting deadlines. It becomes crucial how overseas safety information is collected, evaluated, recorded, and under which regulatory framework it is submitted and managed.
For overseas manufacturers expanding into Japan, the design of the safety management system with the in-country marketing authorization holder (MAH) is directly linked to stable post-approval operations.
3. Post-Approval Commercialization, Reimbursement, and Supply Systems are Becoming More Crucial
The approval of Saviskas® Injection and the establishment of NovAccel's medical RI supply system demonstrate that, in the commercialization of medical technology, not only regulatory approval but also manufacturing, supply, medical institution operation, and reimbursement are critical.
Especially in fields like regenerative medicine products and medical RIs, the post-approval supply system and revenue model design are key to widespread adoption.
7. Checklist for Companies
Medical device and regenerative medicine product developers, overseas manufacturers, and marketing authorization holders in Japan should review the following points based on this week's trends.
Regulatory Affairs and Safety Management
- Is the procedure for collecting, evaluating, and reporting foreign adverse event information compliant with the latest notifications?
- Are there any products subject to post-market surveillance (PMS) evaluation?
- Is it necessary to revise GVP procedures and SOPs?
- Is the safety information exchange agreement with the overseas manufacturer sufficient?
Development and Approval Strategy
- Is the division of regulatory responsibility clear when incorporating AI and software?
- Is the combination use with robot-assisted technology and peripheral devices anticipated?
- Has the determination of whether it's a certification route or an approval route been made at an early stage?
- Has the necessity of clinical evaluation been clarified early on?
Commercialization and Launch Strategy
- Are sales channels secured after approval/certification?
- Are there plans for physician evaluation, facility adoption, and training?
- Is there a clear outlook for health insurance listing and reimbursement prices?
- Is there a balance between manufacturing costs and reimbursement prices?
- Are regulatory, quality, and supply systems considered for overseas expansion?
8. Summary
In early May 2026, medical device and pharmaceutical affairs news saw simultaneous movement across several critical themes, including regulatory operational reviews, endoscopic robots, surgical assistance AI, non-invasive sensors, regenerative medical products, and medical radioisotopes (RIs).
Particularly noteworthy is the shift of medical devices from standalone products to complex medical technologies that incorporate AI, robots, software, and data. This change necessitates a comprehensive pharmaceutical affairs strategy that goes beyond merely "obtaining approval or certification," extending to change management, post-market safety management, health insurance reimbursement, supply systems, and sales channels.
MK Consulting offers consistent support for medical devices from early development through post-market launch, including pharmaceutical affairs applications, PMDA consultations, third-party certifications, health insurance reimbursement, and support for overseas manufacturers entering the Japanese market.
Reference Links
Regulatory Affairs
- Ministry of Health, Labour and Welfare | PMSB/MD Notification No. 0424-1: Revision of the 30-day adverse event reporting for known deaths or serious adverse events involving foreign medical devices
- Ministry of Health, Labour and Welfare | PMSB/MD Notification No. 0424-4: Revision of the 30-day adverse event reporting for known deaths or serious adverse events involving foreign regenerative medical products
Medical Devices, Medical AI, and Startups
- Olympus | Concludes Global Sales Agreement with South Korean Company EndoRobotics
- Anaut | Launches "EUREKA Inside" Business as AI Platform for Operating Rooms
- Light Touch Technology | Raises Additional 500 Million Yen to Develop Needle-Free Blood Glucose Sensor
- NovAccel | Secures 1.2 Billion Yen in Post-Seed Round Funding
Regenerative Medical Products and Clinical Trials
- Fujifilm Toyama Chemical | Obtaining Manufacturing and Marketing Approval for "SAIBISUCUS® Injection," a Regenerative Medical Product for Meniscus Injury
- CoreTissue BioEngineering | Japanese Medtech Startup CoreTissue BioEngineering Initiates Randomized Controlled Cohort in the Clinical Trial for Anterior Cruciate Ligament (ACL) Reconstruction Treatment
Financial Results and Corporate Information
- Sysmex | Recording of Impairment Loss and Revision of Full-Year Consolidated Financial Forecast for the Fiscal Year Ending March 2026
- M3, Inc. | Financial Results for the Fiscal Year Ending March 2026
- Ono Pharmaceutical Co., Ltd. | Financial Results for the Fiscal Year Ending March 2026
- Kyowa Kirin Co., Ltd. | Financial Results for the First Quarter of the Fiscal Year Ending December 2026
- Zeria Pharmaceutical Co., Ltd. | Financial Results for the Fiscal Year Ending March 2026
- Daiichi Sankyo Co., Ltd. | Press Release List